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The growth of vesicular stomatitis virus requires two distinct RNA synthetic events: transcription of messenger RNA
molecules and replication of the viral genome RNA. We report the use of a panel of monoclonal antibodies directed against
the viral phosphoprotein P in an attempt to assess the role of this protein in RNA synthesis. Using extracts derived from
virus-infected cells, we show that several anti-P monoclonal antibodies can have an inhibitory effect on genome RNA
replication by binding to a soluble form of the P protein. We also show that the P protein to which one of these antibodies
(6D11) is directed is not complexed with the N protein and that the amount of soluble P protein that binds to the 6D11
antibody in immunoprecipitation reactions can be increased by treating extracts with alkaline phosphatase. In addition,
phosphatase treatment of infected cell extracts results in an increased level of genome RNA replication. These results
suggest that a soluble subspecies of the P protein that functions in genome RNA replication exists in infected cells and
that this species of the P protein is not required for transcription. q 1996 Academic Press, Inc.
INTRODUCTION ters and Banerjee, 1986). Phosphorylation of specific res-
idues on the P protein has been shown to be important
Vesicular stomatitis virus (VSV) is a rhabdovirus that
in regulating the activity of P protein in transcription
has a negative sense RNA genome of 11,161 nucleotides
(Chattopadhyay and Banerjee, 1987; Barik and Banerjee,
(Banerjee and Barik, 1992). Upon infection of a cell, the
1992a, 1992b; Beckes and Perrault, 1992; Gao and Len-
virus carries out two distinct RNA synthetic activities. The
ard, 1995) as well as replication (Chang et al., 1994). It
viral polymerase initially transcribes a short untranslated
is clear that the RNA synthetic activities of the virus are
leader RNA and five capped, methylated, and polyadenyl-
regulated, at least in part, by site-specific phosphoryla-
ated mRNAs. These mRNAs are subsequently translated
tion of the P protein.
into viral proteins which are required for the second type
Antibodies specific for VSV proteins have been utilized
of RNA synthesis, genome replication. Replication results
in many studies as probes for examining the possible
in the synthesis of full-length positive and negative sense
functions of the proteins (Imblum and Wagner, 1975; Car-
RNA molecules which are neither methylated nor polyad-
roll and Wagner, 1978; De et al., 1982; Harmon and Sum-
enylated. These RNAs must be encapsidated by the N
mers, 1982). In this study we took advantage of the previ-
protein in order to function as templates themselves.
ous work of Williams et al. (1988a, 1988b) who produced
While protein synthesis is known to be required for repli-
a panel of monoclonal antibodies directed against the P
cation of genome RNA, the precise viral proteins needed
protein of VSV. They previously reported the characteriza-
for optimal replication have not been established. The N
tion of the antibodies and their effects in an in vitro tran-
protein is required to encapsidate the nascent RNA and
scription system using purified virions. We report here
it has been shown that the substrate for this process in
our results employing these anti-P protein antibodies in
infected cells is a 1:1 molar complex of N and P proteins
an in vitro system derived from VSV-infected cells (Peluso
(Peluso and Moyer, 1984, 1988; LaFerla and Peluso,
and Moyer, 1983), where we can assess the effect of
1989). The L and P proteins are also required as part of
these antibodies on both transcription and genome RNA
the replicase but it is unknown whether these proteins
replication. Our results lead us to hypothesize that a
are identical to those in the viral transcriptase.
soluble form of the P protein that is not bound to the N
The P protein is phosphorylated in virions and infected
protein functions during genome RNA replication and
cells and it has been previously shown that there are
that this P protein is distinct from that required for tran-
functional subsets of P protein which differ in the degree
scription of the viral genome. Our results also lend further
of phosphorylation (Kingsford and Emerson, 1980; Mas-
support to the hypothesis that phosphorylation of the P
protein regulates its function during replication as well
as transcription.1 To whom reprint requests should be addressed.
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MATERIALS AND METHODS at 10,000g for 1 min and the antibody-depleted superna-
tants were removed and reconstituted with viral RNPs.
Cells and viruses [32P]UTP was then added and the reactions were incu-
bated as above. The resultant RNAs were either ex-The baby hamster kidney (BHK) cell line was used for
tracted directly from the reactions or after treatment withall cell culture in this study. Stock preparations of the HR
micrococcal nuclease to digest unencapsidated RNAstrain of VSV-Indiana and the Mudd-Summers DI-T (MS-
(Peluso and Moyer, 1988). The RNAs were then analyzedT) defective interfering particles were prepared as de-
by acid-urea-agarose gel electrophoresis as describedscribed (Peluso and Moyer, 1983).
(Peluso and Moyer, 1983).
Antibodies
Isotopic labeling of viral proteins
Polyclonal antibody against VSV-Indiana was pur-
Viral specific proteins were labeled using [35S]-chased from Lee Biomolecular Research Inc. (San Diego,
methionine. Virus-infected cell cultures were incubatedCA). The panel of 13 monoclonal antibodies against the
in methionine-free MEM containing [35S]methionine (200viral P protein were kindly provided by Dr. Suzanne Emer-
mci/ml) for 90 min at 2.5 hr pi. After labeling, solubleson while the anti-N antibody was a gift from Dr. Douglas
proteins were prepared following permeabilization as de-Lyles. Cells producing the 6D11 monoclonal anti-P pro-
scribed above.tein antibody were provided by William Sutherland, Uni-
versity of Virginia. These cells were cultured in serum-
Immunoprecipitation of radiolabeled viral proteinsfree medium and the antibody was purified from the cul-
ture medium by protein G-agarose chromatography. Viral proteins were isolated by immunoprecipitation
with both polyclonal and monoclonal antisera in a solu-
In vitro RNA synthesis tion containing 0.5% NP-40 (LaFerla and Peluso, 1989).
Radiolabelled viral proteins were resolved by a sodiumFor the analysis of viral RNA synthesis, subconfluent
dodecyl sulfate–polyacrylamide gel electrophoresis sys-monolayers of cells (107 cells in a 100 mm dish) were
tem described by Beckes and Perrault (1991).infected with VSV at a multiplicity of infection of 10 with
or without a stock suspension of the MS-T DI particle (5
Enzymatic dephosphorylation
ml per 107 cells; Peluso and Moyer, 1983). At 4 hr p.i.,
extracts were prepared by lysolecithin-mediated permea- Radiolabeled soluble proteins prepared as described
above were treated with bacterial alkaline phosphatasebilization and RNA synthesis was measured by incorpo-
ration of [a-32P]UTP (Peluso and Moyer, 1983). Each reac- (BAP) from Escherichia coli (U.S. Biochemical, Cleveland,
OH). The dephosphorylations were done in a buffer con-tion contained 5 1 106 cells in a volume of 200 ml. The
indicated antibodies were added to the extracts, mixed, taining 100 mM HEPES, pH 8.25; 100 mM NH4Cl; 7 mM
KCl; 10 mM MgCl2 ; and 1 mM dithiothreitol. The BAP wasand placed on ice for 2 hr. Then [a-
32P]UTP (100 mCi/
reaction) was added and the reactions were incubated added to each sample and the tubes were incubated at
307C for 1 hr. Following BAP treatment, the samples werefor 1 hr at 307. In the experiments assaying reconstituted
RNA synthesis, cell extracts were fractionated by ultra- immunoprecipitated as described above. For the BAP
treatment of infected cell extracts prior to RNA synthesis,centrifugation through 30% glycerol on a pad of 99% glyc-
erol as described previously (Peluso and Moyer, 1983). the enzyme was added directly to these samples and
they were incubated for 60 min at 307C. Following de-After centrifugation, the soluble protein fraction was col-
lected from the top of the gradient, the 30% glycerol frac- phosphorylation, the BAP was inactivated by addition of
NaPO4 (Fernley and Walker, 1969), fresh NTPs weretion was discarded, and the viral RNPs were collected
by suspending the top of the 99% glycerol cushion in added, and RNA synthesis was assayed as above.
reaction mix. The two fractions were combined to recon-
stitute RNA replication. For the experiments determining RESULTS
the effects of antibodies on reconstituted RNA synthesis,
Effect of antibodies to VSV proteins on in vitro RNA
immunoprecipitations of the soluble protein pool were
synthesis
performed prior to reconstitution. Antibodies were added
to 20 ml of protein G sepharose beads (50% in PBS). The work of Williams et al. (1988a, 1988b) suggested
that the monoclonal anti-P antibodies bind to differentThe samples were rotated for 120 min at 47C then the
antibody–protein G sepharose complexes were washed functional domains within the P protein present in the
virus particle. In order to determine the effects of thefive times in 1 ml reaction mix. The antibody-coated
beads were then used to precipitate specific proteins panel of monoclonal anti-P antibodies on viral transcrip-
tion and genome RNA replication in infected cell extracts,from the soluble protein fractions for 1 hr while rotating
at 47C. The complexes were removed by centrifugation each antibody was added to a separate in vitro RNA
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transcription to a limited extent, possibly due to their
effects on replication and subsequent secondary tran-
scription. We investigated the extent of this effect by
adding higher concentrations of the 6D11 monoclonal
antibody to in vitro RNA synthesis reactions (Fig. 2). Ge-
nomic RNA synthesis was blocked by as low as 1 mg
of the antibody while transcription was able to proceed
despite large amounts of antibody. The inhibition of tran-
scription by this antibody reaches a plateau. This de-
crease in transcription may be a secondary effect of the
antibody’s ability to prevent new nucleocapsid synthesis,
thereby reducing the number of transcriptionally active
templates in the reactions. In no experiments were any
of the anti-P antibodies (except 2A2, which cross-reacts
with the N protein) able to totally inhibit transcription. In
most of our following experiments, we utilized primarily
the 6D11 antibody since we were able to obtain the hy-
bridoma cell line which produces this antibody and it
FIG. 1. Effect of antibodies to VSV proteins on in vitro RNA synthesis.
had a specific effect on replication of VSV genome RNAThe 32P-labeled RNAs synthesized in the presence of 2 mg of the indi-
at low concentrations.cated antibodies were isolated and electrophoresed on a 1.5% acid
urea agarose gel. The top panel shows the RNAs present after diges-
tion with micrococcal nuclease while the lower panel shows isolated Ability of soluble proteins to support reconstituted
total RNA. The positions of the viral mRNAs and 42S genomic RNAs replication after removal of specific proteins
are indicated.
In infected cells, the P protein is found both soluble
and associated with the ribonucleoprotein complex. Anti-
synthesis reaction. Extracts of VSV-infected BHK cells
body to the P protein could affect genome RNA replica-
were prepared, incubated with 2 mg of the indicated
monoclonal antibody on ice, and then [32P]UTP was
added to label the products of RNA synthesis. The 32P-
labeled RNAs synthesized in the presence of the antibod-
ies are shown in Fig. 1. The bottom panel depicts RNA
transcripts produced in the reactions and the top panel
shows the nuclease-resistant 42S VSV genomic RNA
band indicative of replication. An untreated reaction and
an anti-N monoclonal antibody-treated reaction were in-
cluded as controls (lanes 1 and 2). The anti-N and the
anti-P 2A2 antibodies blocked RNA synthesis completely
(bottom and top panels, lanes 2 and 4). The 2A2 antibody
has been shown to cross-react with in vitro-synthesized
N protein (Williams et al., 1988b) so this antibody and
the anti-N antibody probably inhibited RNA synthesis by
binding to N protein on the nucleocapsid template. None
of the antibodies which react exclusively with P protein
were able to totally block transcription, even when higher
concentrations of antibodies were used (data not shown,
see Fig. 2). The effect of the antibodies on viral genome
replication was determined by examining the nuclease
resistant encapsidated RNAs (top panel, fig. 1). Several
of the anti-P antibodies (6D11, 4F11, 2F2, and 6H1) inhibit
genome RNA synthesis and nucleocapsid assembly (fig.
1; lanes 3, 5, 7, 15). The two antibodies that bind the N
protein, anti-N and 2A2, and blocked transcription also
blocked replication. FIG. 2. Effect of increasing amounts of 6D11 anti-P monoclonal anti-
In some experiments, some of the anti-P antibodies body on in vitro RNA synthesis. The amounts of antibody used are
shown above each lane.that block genome RNA replication also inhibited viral
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tion either by binding to P protein on the RNA template
or by binding to a soluble form of the P protein that
functions in genome RNA synthesis. Most of the P protein
found in cells is in a soluble pool and not associated
with the RNP (Peluso, 1988) and therefore it is likely that
the anti-P protein antibody would bind to this pool of
soluble P protein rather than to the RNP. Also, binding
of antibody to the RNP would block both replication and FIG. 3. Effect of antibodies on RNA synthesis by reactions reconstitu-
transcription. Since we have shown an effect of several ted from fractionated WT and DI coinfected cell extracts. The 32P-la-
beled, nuclease-resistant RNAs synthesized from reactions combininganti-P protein monoclonal antibodies on genome RNA
RNPs with soluble protein depleted using 2 mg of the indicated antibod-replication but not on transcription (Figs. 1 and 2), we
ies were isolated and electrophoresed on a 1.5% acid urea agarose
compared the sensitivity of viral and cellular nucleocap- gel. The bands shown correspond to the (/) (bottom) and (0) (top)
sids for inhibition of transcription by the 6D11 antibody. sense MS-T DI genome RNA.
We found (our unpublished data) that transcription is
blocked in an identical manner by the 6D11 antibody
anti-P monoclonals there was no effect on RNA synthe-regardless of the source of the nucleocapsid template,
sis. The above data suggests that a soluble form of thein agreement with the results of Williams et al. (1988b).
P protein is required for genome RNA replication in theseThis result indicates that the antibody can block tran-
reactions and that the anti-P antibodies which block rep-scription by binding to P protein on either template. In
lication react with this P protein. As expected, depletionthe experiments presented here, using infected cell ex-
of soluble protein by all of the antibodies had no affecttracts, the large pool of soluble P protein present in the
on reconstituted transcription, since the soluble proteinextracts probably binds the antibody and limits the
is not needed for this process (data not shown). Theamount available to interact with the RNPs.
virus requires not only an N:P protein complex for ge-To determine directly whether soluble P protein was
nome RNA replication, but apparently another form ofinvolved in replication, we tested whether removal of
soluble P protein in order for replication and encapsida-antibody-bound proteins from the soluble protein fraction
tion to occur.was able to affect RNA synthesis when added to the RNP
templates. An infected cell extract was fractionated into
Effect of removal of N-P complexes on
a soluble protein fraction and a pellet fraction containing
immunoprecipitation by anti-P antibodies
the RNP template. If these fractions are recombined, both
transcription and genome RNA replication are reconstitu- We have shown that a 1:1 complex between the N and
P proteins exists in the soluble protein fraction of infectedted (Peluso and Moyer, 1983). The RNP fraction alone
can carry out transcription of mRNAs, but the soluble cells and is used for genome RNA replication and encap-
sidation (Peluso and Moyer, 1984, 1988; La Ferla andprotein fraction is needed for genome RNA replication to
occur. Cells coinfected with wild-type VSV (WT) plus the Peluso, 1989). It was possible that the 6D11 anti-P anti-
body was interacting with soluble P protein that wasMS-T defective-interfering (DI) particle were used for
these experiments in order to more easily assess ge- bound to N protein. Such a specificity would explain the
ability of this antibody to block genome RNA replication.nome RNA replication. The DI genome is smaller than
WT and essentially only replicates, resulting in the syn- Some of our data argued against this possibility. When
immunoprecipitations were done under conditions whichthesis of high levels of DI genomic RNA relative to WT.
The antibodies were added to the soluble protein fraction allowed the detection of N:P complexes, the 6D11 anti-
body was one of the least effective antibodies in precipi-of the extracts, allowed to react, and then antigen–anti-
body complexes were removed. The resulting depleted tating these complexes (Figs. 4, 5, 6; lanes 6D11). One
of the other anti-P antibodies (4F11) precipitated fourfoldsoluble protein was then reconstituted with the nucleo-
capsids in the pellet fraction, and RNA synthesis was more of N:P complexes than 6D11 (Williams et al., 1988a
and data not shown) and yet was not more effective atanalyzed (Fig. 3). Soluble protein depleted using the
monoclonal antibodies which were shown to block repli- blocking replication. However, in repeated experiments,
the 6D11 antibody has been shown to be the most effec-cation in complete extracts no longer supported DI ge-
nome RNA replication (Fig. 3, lanes 3–6), while the solu- tive at blocking replication. Thus, the 4F11 and 6D11
antibodies, although both effective at inhibiting replica-ble protein depleted using normal rabbit serum was repli-
cation competent (lane 7). The soluble protein depleted tion, most likely do so in distinctly different ways. This
evidence, although indirect, suggests that it is not thewith the anti-N monoclonal antibody no longer supports
genome RNA synthesis (lane 2), an expected result since removal of N:P complexes which results in the block of
genome RNA replication by the 6D11 monoclonal anti-the N protein is required for nucleocapsid assembly.
When soluble protein was treated with any of the other body. The 4F11 antibody apparently blocks replication
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FIG. 5. Immunoprecipitation of untreated and BAP-treated soluble
protein by antibodies to VSV proteins. Lanes 1–3 were immunoprecipi-
FIG. 4. Immunoprecipitation of 35S-labeled, VSV-infected cell soluble tations of untreated 35S-labeled soluble protein while lanes 4–6 were
proteins. Soluble proteins were prepared from 35S-labeled-infected treated with BAP prior to immunoprecipitation with 1 mg of the indicated
cells and divided into two samples. One sample was untreated (normal) antibodies. The positions of the viral P and N proteins are indicated.
while the other was depleted of N–P complexes by immunoprecipita-
tion four times with 5 mg each of anti-N antibody (depleted). These two
samples were each divided three ways and further immunoprecipitated unpublished data). These experiments demonstrate the
using 1 mg of the indicated antibodies. The immunoprecipitates were existence in VSV-infected cells of a soluble form of the
analyzed by polyacrylamide gel electrophoresis on an 11% gel as de-
P protein that is not complexed to the N protein and thatscribed in the methods section. The positions of the viral P and N
this form of the P protein is required for genome RNAproteins are indicated.
replication and nucleocapsid assembly, but not for tran-
scription of viral mRNA.
by reacting with the N:P protein complex, a result which
The effect of alkaline phosphatase treatment onstrengthens the hypothesis that this protein complex
immunoprecipitation of infected cell proteinsfunctions during replication.
To further investigate the possibility that the 6D11 anti- The P protein exists in infected cells as a heteroge-
body was binding to P protein that was not complexed neous pool of differentially phosphorylated molecules
with the N protein, we tested the monoclonal anti-P anti- (Hsu and Kingsbury, 1982). Since phosphorylation of P
body 6D11 for its ability to precipitate the P protein from has been shown to regulate the function of the protein
soluble protein that had been previously depleted of the in RNA synthesis and we had shown that the P protein
N:P protein complex. Soluble protein (35S-labeled) from which bound to the 6D11 antibody is functionally different
VSV-infected cells was depleted of the N:P protein com- from other P protein, we wanted to know if there was a
plex by repeated immunoprecipitation with an anti-N discernible structural difference in the phosphorylation
monoclonal antibody and then the complex-depleted sol- pattern of the 6D11-reactive P. Other studies have shown
uble protein that remained was reacted with the mono- that phosphorylated P protein can be dephosphorylated
clonal anti-P antibody 6D11 (Fig. 4). As controls, the pro- by BAP (Kingsbury et al., 1981; Hsu et al., 1982) so we
tein samples were also precipitated with a polyclonal decided to use this enzyme to try and identify a structural
rabbit anti-VSV serum and an anti-N monoclonal anti- difference that distinguishes the P protein recognized by
body. It should be noted that the anti-VSV polyclonal the 6D11 antibody from other forms. If the 6D11 antibody
antisera has a very low titer against the P protein and recognizes an epitope that is conformationally depen-
does not precipitate much of this protein in immunopre- dent on phosphorylation, then dephosphorylation of the
cipitation experiments. Lanes of gels using this antise- P protein would affect the binding of the antibody. We
rum in Figs. 4–6 are not quantitative for the P protein. used BAP to dephosphorylate 35S-labeled soluble protein
The treatment of the soluble protein was effective in re- and then performed immunoprecipitations as before.
moving the N protein and the N:P protein complex (com-
pare lanes 1 to 2, and lanes 3 to 4), yet the amount of P
protein precipitated by the 6D11 antibody was not af-
fected (lanes 5 and 6). Lanes 1, 3, and 5 were analyzed
prior to N-depletion, and lanes 2, 4, and 6, after. This
result indicated that the P protein to which the 6D11
monoclonal antibody is directed is not the form of P
that is complexed to the N protein. This conclusion was
further supported by the finding that prior immunoprecipi-
tation of soluble protein by an amount of 6D11 antibody FIG. 6. Immunoprecipitation of soluble proteins treated with varying
sufficient to inhibit replication did not reduce the amount amounts of BAP. Notation and immunoprecipitations are similar to
those described in the legend of Fig. 5.of N:P complex available in the soluble protein pool (our
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in reactivity of the 6D11 antibody with P protein is much
larger than that needed to stimulate replication. As a
control for the possibility that a contaminant in the BAP
preparation was responsible for the increased genome
RNA synthesis rather than the BAP itself, we inhibited
the enzymatic activity with inorganic phosphate prior to
FIG. 7. Effect of BAP on synthesis of nuclease-resistant RNA by VSV- its addition to reactions, and, as expected, the stimulation
infected cell extracts. VSV wild-type and DI coinfected cell extracts (106 of genome RNA replication was blocked.
cells/lane) were treated with BAP (lane 1, 0 units; lane 2, 0.03 units;
lane 3, 0.15 units; lane 4, 0.3 units; lane 5, 0.6 units; lane 6, 1.2 units)
and then the 32P-labeled, nuclease-resistant RNAs were isolated and DISCUSSION
analyzed as described in the methods. The top band is the minus
sense DI genome RNA, and the bottom, the plus sense. The phosphoprotein P of VSV is known to have multiple
functions in infected cells. It is an essential subunit of the
viral RNA polymerase and is thought to bind directly to the
Treatment of infected cell soluble protein with BAP
nucleocapsid template and facilitate the association of the
(Fig. 5; lanes 4–6) resulted in an increase in the amount
catalytic subunit, the L protein, to the template (Mellon and
of the P protein that is immunoprecipitated by the 6D11
Emerson, 1978; Thornton et al., 1984). The P protein alone
antibody (compare lanes 3 and 6). In contrast, the amount
is not believed to have an enzymatic function during RNA
of P protein reactive with the 2E1 anti-P protein mono-
synthesis. In addition, the P protein also functions during
clonal antibody, which has no effect on genome RNA
genome RNA synthesis by complexing with the N protein
replication (see Fig. 1), decreased (lanes 2 and 5). The
to form the functional substrate for the encapsidation of
amount of protein precipitated by the polyclonal anti-VSV
newly synthesized genome-length RNAs (Peluso and
serum remains unchanged by BAP treatment (lanes 1
Moyer, 1984, 1988; LaFerla and Peluso, 1989). The P protein
and 4). The above results were confirmed using increas-
which binds to N protein apparently functions as a chaper-
ing amounts of BAP (Fig. 6). The total amounts of N and
one to prevent free N protein from self-assembling into
P proteins precipitated by anti-VSV and anti-N antibodies
inactive complexes. The N:P complexes bind to newly syn-
did not change with enzyme treatment (first 8 lanes), but
thesized replication products during nucleocapsid assem-
the amount of 6D11-reactive P protein increased as the
bly. In this process, the complex is dissociated and the P
amount of enzyme increases (lanes 9–12). Quantitation
protein is released into the cytoplasm while the N protein
of the respective bands of this gel revealed a 45% in-
becomes bound to the nucleocapsid. It is possible that the
crease in the P protein precipitated by the 6D11 antibody
P protein has additional, unknown functions during the life
after BAP treatment. Therefore, the epitope recognized
cycle of VSV.
by this antibody is available for binding when a potential
Since the P protein exists in cells and virions as a
phosphorylation site is not phosphorylated.
heterogeneous population of differentially phosphory-
lated molecules, it has been hypothesized that the func-The effect of dephosphorylation of infected cell
tion of P is regulated by phosphorylation. Recent studiesextracts on in vitro RNA synthesis
have made it clear that phosphorylation of specific resi-
dues within the P protein regulates its function in RNASince we could increase the amount of the P protein
that is reactive with the 6D11 antibody by treatment with synthesis. The phosphorylation of two amino acids in the
amino terminal half of the P protein by casein kinase IIBAP, and since this form of the protein is needed for
genome RNA replication, we tested the effect of BAP has been shown to be required for the activity of the P
protein in transcription (Barik and Banerjee, 1992a,treatment of cell-free extracts on genome RNA replica-
tion. Our experiments involved adding BAP to cell ex- 1992b; Gao and Lenard, 1995). Recently, it has also been
suggested that phosphorylation of P regulates its activitytracts made from WT and DI coinfected cells and incubat-
ing for 1 hr. The BAP was then inhibited by adding inor- during replication as well (Chang et al., 1994).
We present evidence here that indicates that a solubleganic phosphate, fresh NTPs were added, and the
extracts were incubated at 307C to allow RNA synthesis form of P protein performs an essential function during
genome RNA replication that is unnecessary during viralto proceed. The treatment of infected cell extracts with
BAP resulted in increased production of nuclease-resis- transcription. This hypothesis is based on the fact that
several anti-P monoclonal antibodies, when used to spe-tant genome RNA (Fig. 7). This stimulation of RNA replica-
tion was dose-dependent with the most genome RNA cifically remove proteins from soluble protein fractions
of VSV-infected cells that support replication of the viralmade at the highest level of added BAP. In addition, there
was a concomitant decrease in the level of transcription genome, block genomic RNA synthesis and nucleocap-
sid assembly while having no effect on transcription byin these reactions (data not shown). It is important to
point out that the amount of BAP required to see a change reconstituted reactions. The anti-P antibody 6D11 was
/ 6a0f$$7674 01-12-96 08:18:21 viras AP-Virology
32 RICHARDSON AND PELUSO
able to inhibit replication by binding to soluble P protein antibody. The dephosphorylation of soluble protein by
BAP results in more P protein being available for bindingthat was not complexed with N protein. This distinction
is important since P protein complexed with the N protein to the 6D11 antibody but less for binding to the 2E1
antibody. Williams et al. (1988a) mapped the binding sitesis used for the production of encapsidated, full-length
genome RNA in infected cells (Peluso and Moyer, 1984, of these antibodies to the same region, amino acids 177–
227, of the P protein. They also showed that these two1988; LaFerla and Peluso, 1989). In the reconstituted re-
actions discussed in this study, there is a functioning antibodies competed for binding to P protein in plate
binding assays, indicating that they both bind to similarRNA polymerase that is capable of producing transcrip-
tion products. There are also N:P complexes present regions. Our findings indicate that the epitopes bound
by these antibodies are changed by dephosphorylation.which should be able to encapsidate the products of
replicative RNA synthesis. According to one model of The 2E1 antibody binds to a P protein which is phosphor-
ylated at an unspecified site while the 6D11 antibodyreplication (Blumberg et al., 1981; Arnheiter et al., 1985)
these two components should be sufficient to produce binds to P which is not phosphorylated at some site. It
is possible that these antibodies bind to epitopes whichfull-length genomic RNAs in infected cells. However, in
soluble protein depleted of 6D11-reactive P protein there are affected by phosphorylation of the same amino acid,
but this remains to be determined. The treatment of solu-is a loss of the ability to support replication. At this time
we are unable to determine the specific function of this ble protein by BAP does remove labeled phosphate from
P protein (our unpublished data), but does not changesoluble P protein during the replication process. The
6D11 bound P protein does associate in a soluble com- its migration in SDS–PAGE, at least in our hands. The P
protein precipitated by the 6D11 antibody comigratesplex with some L protein (our unpublished data). The
removal of this small amount of L–P complex has no with the NS1 subspecies of P protein described by others
(Clinton et al., 1979) that is less active in transcriptioneffect on transcription but the loss of L protein could
contribute to the inability of the depleted soluble protein than the more highly phosphorylated NS2 form.
It is important to note that the amount of BAP used toto support replication.
The present study is an extension of the previous work demonstrate an increase in P protein binding by mono-
clonal antibody 6D11 is much greater than the amountof Williams et al. (1988a, 1988b). Their work showed that
different monoclonal anti-P antibodies could affect differ- required to stimulate genome replication. There may not
be a direct correlation between the measured increaseent steps of viral transcription when added to an in vitro
system consisting of disrupted virions. In those studies, in 6D11 precipitable P protein and the increase in ge-
nome RNA replication. However, it is also possible thatthe 6D11 antibody was able to block the initiation of RNA
synthesis by viral nucleocapsid templates while other the enzyme treatment is in fact stimulating the level of
genome RNA replication by its action on the P protein,antibodies blocked the elongation of initiated transcripts.
It is possible that the soluble P protein bound by 6D11 and this is not being seen in the immunoprecipitation
assays we employed, where subtle changes in proteinis involved in the initiation of replication but not initiation
of transcription. The experiments described in this paper levels would not be detected. It is also possible that the
increase in replication seen after phosphatase treatmentcannot discriminate between the inhibition of initiation of
replication and inhibition of later steps in the replicative is due to dephosphorylation of another, unknown, viral
or cellular protein. Obviously, all of these possibilitiesprocess. However, the 6D11 antibody is able to block
transcription by either virus or cell-derived RNPs. In the need to be fully investigated before firm conclusions may
be drawn.infected cell extract system used in these experiments,
it is the large pool of soluble P protein available that Recently published results support our suggestion that
an incompletely phosphorylated form of the P protein isallows the distinction between transcription and replica-
tion to be made by this antibody. required for the production of full-length genome RNAs
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